Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Depreciation (2016 - 2025)

Altimmune (ALT) has disclosed Accumulated Depreciation for 6 consecutive years, with $2.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation rose 12.05% to $2.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.2 million, a 12.05% increase, with the full-year FY2024 number at $2.2 million, up 12.05% from a year prior.
  • Accumulated Depreciation was $2.2 million for Q4 2024 at Altimmune, up from $2.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $2.2 million in Q4 2024 to a low of $1.5 million in Q4 2022.
  • A 5-year average of $1.9 million and a median of $1.9 million in 2021 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: decreased 26.82% in 2022, then soared 31.84% in 2023.
  • Altimmune's Accumulated Depreciation stood at $1.6 million in 2020, then grew by 28.03% to $2.0 million in 2021, then fell by 26.82% to $1.5 million in 2022, then soared by 31.84% to $2.0 million in 2023, then increased by 12.05% to $2.2 million in 2024.
  • Per Business Quant, the three most recent readings for ALT's Accumulated Depreciation are $2.2 million (Q4 2024), $2.0 million (Q4 2023), and $1.5 million (Q4 2022).